Why Researchify Health Has Incredible Impact
Kidney disease affects 35+ million Americans, yet most never hear about trials that could slow progression or delay dialysis. Researchify Health brings these opportunities directly to patients and care teams through automated, human-like SMS. Sites keep the relationship while our flows create early awareness, simplify pre-screening, collect structured data, and coordinate next steps across community nephrology practices.
Key Benefits for Nephrology
Close the awareness gap
Patients actually learn about relevant studies—without intrusive calls or portal logins.
Early identification
Lab-triggered and checklist SMS flows surface potentially eligible patients sooner.
Fewer screen failures
Structured intake reduces missing lab/medication data that can push renal trial screen-fail rates above 45%.
Caregiver inclusion
Two-way SMS engages caregivers for transportation, consent, and reminders—automatically.
Equity at scale
Multilingual outreach (10+ languages) helps include underrepresented CKD populations.
Coordinator time saved
Automated pre-screening and document collection cut manual outreach and back-and-forth.
Meet Jane
1 in 7 (≈15%)
U.S. adults with chronic kidney disease
<10%
CKD patients ever informed about research by their nephrologist
<1%
CKD patients participating in research
70%+
Nephrology patients receiving care in community settings
45%+
Potential screen-failure rate from missing/incomplete data
80+
Languages supported
Challenges We Address
Massive unmet awareness:Fewer than 10% of CKD patients report being told about a study by their nephrologist.
Community setting limitations:Over 70% receive care outside academic centers, where research awareness is minimal.
Fragmented data: Missing labs/med lists drive screen-fail rates above 45% in renal trials—our structured intake mitigates this.
Caregiver coordination: Many CKD and dialysis patients rely on caregivers; our two-way SMS engages both parties.
Equity gap: CKD rates are up to 3× higher among Black and Hispanic adults, yet these groups remain underrepresented; multilingual SMS helps close the gap.
Low participation baseline: Despite high prevalence (1 in 7 U.S. adults), fewer than 1% of CKD patients participate in research.